第一单位：
Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore, Maryland, USA.
作者：
Sara L,Deschaine [1]
;
Mehdi,Farokhnia [2]
;
Adriana,Gregory-Flores [3]
;
Lia J,Zallar [3]
;
Zhi-Bing,You [4]
;
Hui,Sun [5]
;
Deon M,Harvey [6]
;
Renata C N,Marchette [7]
;
Brendan J,Tunstall [8]
;
Bharath K,Mani [9]
;
Jacob E,Moose [10]
;
Mary R,Lee [1]
;
Eliot,Gardner [4]
;
Fatemeh,Akhlaghi [11]
;
Marisa,Roberto [12]
;
James L,Hougland [13]
;
Jeffrey M,Zigman [14]
;
George F,Koob [8]
;
Leandro F,Vendruscolo [8]
;
Lorenzo,Leggio [15]
作者单位：
Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore, Maryland, USA.
[1]
Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore, Maryland, USA.;Center on Compulsive Behaviors, National Institutes of Health, Bethesda, Maryland, USA.;Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
[2]
Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore, Maryland, USA.;Neurobiology of Addiction Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
[3]
Neuropsychopharmacology Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
[4]
Clinical Core Laboratory, Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
[5]
Office of the Scientific Director, National Institute on Drug Abuse, Baltimore, Maryland, USA.
[6]
Center on Compulsive Behaviors, National Institutes of Health, Bethesda, Maryland, USA.;Neurobiology of Addiction Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
[7]
Neurobiology of Addiction Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
[8]
Center for Hypothalamic Research, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
[9]
Syracuse Biomaterials Institute, Syracuse University, Syracuse, New York, USA.;Department of Chemistry, Syracuse University, Syracuse, New York, USA.
[10]
Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island, USA.
[11]
Department of Neuroscience, The Scripps Research Institute, La Jolla, California, USA.
[12]
Syracuse Biomaterials Institute, Syracuse University, Syracuse, New York, USA.;Department of Chemistry, Syracuse University, Syracuse, New York, USA.;BioInspired Syracuse, Syracuse University, Syracuse, New York, USA.
[13]
Center for Hypothalamic Research, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.;Division of Endocrinology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.;Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, USA.
[14]
Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore, Maryland, USA.;Center on Compulsive Behaviors, National Institutes of Health, Bethesda, Maryland, USA.;Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.;Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island, USA.;Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.;Department of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA.
[15]
DOI
10.1111/adb.13033
PMID
33908131
发布时间
2023-01-02
换一批
换一批
